The 2024 Medicilon Innovative Drug Industry Ecological Collaboration Conference was a complete success

 On March 18, the Medicilon Innovation Drug Industry Ecological Collaboration Conference was successfully held.  After two decades of hard work, Medicilon takes empowering innovative biopharmaceutical research and development as its mission, grows side by side with China's biopharmaceutical industry, and has developed into a leading one-stop biopharmaceutical preclinical R&D service platform in China.

At the conference, more than 500 industry leaders from the government, industry, academia, finance and other fields gathered to participate in the grand event.  Together, they reviewed Medicilon's outstanding history over the past two decades, witnessing the start of its globalization and the grand launch of two key technology service platforms.

Globalization has begun
Deep empowerment and transformation of innovation results

Medicilon Biopharmaceutical Source Innovation Achievements Transformation Launching Ceremony

At the ceremony, Pharma representative Lianshan Zhang, scientific research institute representative Bin Li, CXO industry representatives Chunlin Chen, Dewan Zeng, and Yiping Rong, AI intellectual drug representative Long Zhang, overseas Biotech representative Mr. Sam Waksal, domestic Biotech representatives Changfu Cheng and Binlei Liu, investor representative Yongsheng Zhao came to the stage and started the transformation of innovative results from the source of biopharmaceutical.  Medicilon will take this launching ceremony as an opportunity to further strengthen communication and collaboration with domestic and foreign partners, jointly explore new paths for the transformation of biopharmaceutical innovation results, work together to promote the continued prosperity and development of the global biomedical industry to create a better future.

Discussion Topic: Sharing of innovative drugs overseas strategies and successful cases

Innovative drugs continue to surge overseas. How to seize the global market?  Under the host of Jing Qiang, Founder & Chairman of Evopoint Bioscience and Founding Partner of Apricot Capital, Lianshan Zhang, Deputy General Manager and Global R&D President of Hengrui Pharmaceuticals; Tongtong Xue, Gounder, Chairman and CEO of MediLink Therapeutics; Jianbiao Peng, President of Jemincare Small Molecule Innovation Research Institute, Wenseng Pan, Partner of the Hong Kong office of Goodwin International Law Firm and Qingcong Lin, President of Medicilon US Corp gathered together to discuss strategies and paths for innovative drugs to go overseas.

Discussion Topic: Sharing of innovative drugs overseas strategies and successful cases

Lianshan Zhang, Tongtong Xue, and Jianbiao Peng shared their respective strategic plans and successful experiences in taking innovative drugs overseas from the practical perspective of pharmaceutical companies.  They elaborated on how to achieve the global layout of innovative drugs through precise positioning, technological innovation and international collaboration, providing useful inspiration for pharmaceutical companies.

Wenseng Pan conducted an in-depth analysis from the legal perspective and elaborated on the many challenges and coping strategies encountered by innovative drugs in overseas markets. She especially shared the case study of Goodwin International Law Firm and provided practical suggestions to the participants.

As an investor and pharmaceutical company representative, Jing Qiang shared Evopoint Bioscience's unique experience in innovative drug research and development and internationalization.  He also mentioned that Apricot Capital has always been concerned about the research and development and industrialization development of innovative drugs, providing funds and resources for potential enterprises and projects, and promoting the globalization process of China's innovative drugs.

From the perspective of a CRO, Qingcong Lin shared Medicilon’s rich experience and profound lessons in assisting pharmaceutical companies to enter the international market.  He emphasized that Medicilon's one-stop biopharmaceutical preclinical R&D service platform can support the entire process of drugs from target discovery to IND application, and the new drug empowerment ecosystem of the Academician Innovative Drug Maturation Center can assist with new drug funding, transactions and other issues.  Currently, Medicilon has established a research and development base in Boston, which will further empower the process of taking drugs overseas and achieve higher value.

Multiple layouts unveiled
Two key technology platforms released

At this grand ceremony, Medicilon's two key scientific technology platforms made their grand debut, attracting widespread attention from the attendees.

1 Key Technology Platform for Drug Discovery & Pharmaceutical Research Science

Jian Liu, Medicilon's President of Drug Discovery & CMC Divisions

Liu Jian, President of Medicilon's Drug Discovery & CMC Divisions, introduced the scientific key technology platform for drug discovery and pharmaceutical research.  The platform includes a targeted protein degradation new drug platform, a small nucleic acid drug R&D platform, an ADC drug R&D platform, a peptide macrocyclic tide drug R&D platform, an AI drug R&D platform, a synthetic biology platform, a green chemistry platform, and a drug metabolite platform, which support innovation in various drug forms.  It is worth noting that Medicilon has a complete research and development platform for small molecule innovative drugs, the AI drug discovery platform that empowers and accelerates new drug research and development from target discovery to the production of preclinical compounds, and Green chemistry platforms and synthetic biology platforms that enable the synthesis of various complex compounds.

2 Key Technology Platforms for Preclinical Research Science

Haizhou Zhang, President of Medicilon's Preclinical R&D Unit

Haizhou Zhang, President of Medicilon's Preclinical R&D Unit, elaborated on Medicilon's key technology platforms for preclinical research science.  In terms of discovery biology, Medicilon has established new in vitro screening platforms, such as PROTAC, small nucleic acids, and ADCs, as well as cutting-edge technologies such as synthetic biology and nanobody discovery.  In terms of pharmacological efficacy, there are advanced platforms such as in vivo imaging, small animal surgical resection, and ex vivo imaging.  In addition, Haizhou Zhang focused on DMPK and safety service platforms for various advanced drug types such as PROTAC, oligonucleotides, ADCs, mRNA, and cellular immunity, as well as preclinical service platforms such as inhaled drugs, ophthalmic drugs, and topical drugs.

The release of two key technology service platforms not only fully demonstrates Medicilon's outstanding strength and profound heritage in the field of biopharmaceutical preclinical research and development, but also provides solid and powerful support for its future efforts to better empower clients.